Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Medical adherence to topical corticosteroid products in psoriasis patients is a main determinant for poor treatment effect.
The investigators aim to test if a multifaceted intervention delivered in an app (MyPso QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM) (Teslo) can improve medical adherence among psoriasis patients treated with a topical calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©).
The study is classified as a phase 4 study, since it is studied if improved use of Enstilar© results in improved treatment outcomes.
Link to published study protocol:
https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3
Link to published results from the study:
Material and methods Intervention: Participants in the intervention group download a patient supporting app (MyPso SmarTopâ„¢ Version 1.0, owned by Leo Pharma) which combined with an EM (SmarTopâ„¢ number 053776, owned by Leo Pharma) has three functions: 1) Measures use of medication through EM, 2) measures degree of psoriasis by patients tracking symptoms, and 3) supports the patient with treatment and refill reminders.
Study type: Single-blind block randomized controlled trial. Sampling: Patients are sampled from the dermatology out-patient clinic at Odense University Hospital.
Eligibility criteria: Psoriasis patients aged 18-75 years with mild-moderate psoriasis. It is mandatory that patients have a smartphone and basic skills for use of the smartphone.
Estimated sample size: To be able to improve medical adherence, the investigators wish to detect an 8 % difference between number of applications between intervention and control arm in use of Enstilar© over a 4 week treatment period. Confidence Interval (two-sided) using 95 % C.I., power 80, ratio of sample size 1, mean number of application in intervention Group 90 % of recommended daily application / 4 weeks, S.D. 15 %, drop-outs maximum 10 %:
Total sample size: 134 participants All participants will be seen by trial principal investigator at all of the study visits.
Disclosure and informed signed consent will be obtained before inclusion: The patients are aware they test new equipments, but not informed that they are being monitored or the purpose of the study.
Randomization: Single-blind block randomized controlled trial. Procedure: At the first study visit the trial investigator obtains information regarding gender, age and estimates use of Enstilar© for 4 weeks based on involved Body Surface Area (BSA).
For randomization the investigators use blocks based on 1) age and 2) gender.
Procedures at baseline study visit: While the patient fills the Dermatology Life Quality Index (DLQI) questionnaire, the trial investigator inserts baseline data into the programme REsearch Data Capture (REDCap©) randomize, which randomizes into an intervention- and control arm. Both intervention- and control group receive Enstilar© in the consultation.
To avoid attrition bias from the prescribing doctor, knowledge regarding which patients that are randomized for the intervention is restricted to one nurse until last study visit. After the consultation the patient is referred to a nearby room, where the nurse has access to see into which group the participant has been randomized. If the participant is randomized to the app group, the nurse will instruct the patient in how to download the app on their smartphone and give standard of care instructions regarding how to adhere to the treatment plan. The participants in the control group will reveive standard of care instructions from the nurse regarding how to adhere to the treatment plan. The nurse will not disclose that the patient is being monitored. At the baseline visit the nurse delivers free study medication (Enstilar©) to all participants.
Baseline: Medical history, socio-economic data, DLQI (Dermatology Life Quality Index) and LS-PGA (Lattice System Physician's Global Assessment).
Primary outcome measure week 4: Rate of secondary nonadherence to Enstilar© is obtained using three different Measurements:
Estimated use 0.5 g Enstilar© / % Body Surface Area (BSA) involved / use of Enstilar© in a 4-week treatment period (measured by weight of Enstilar© cans)
Number of estimated applications in the treatment period / Number of Applied applications in the treatment period (measured by EM)
Reported by the patient on an interval scale
Secondary outcome measures week 4, 8, and 26: DLQI and LS-PGA. At study visit week 4 the patients return the EM to the investigator.
Conclusion: If the app for smartphones with the EM can improve adherence and significantly improve secondary outcome measures long-term (week 26), there are promising potentials for implementing the app in the clinic. To the investigators knowledge, this is the first study in topically treated psoriasis, testing if an intervention delivered by in app for smartphones can improve medical adherence.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| App as intervention + Enstilar© | Experimental | Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation. |
|
| Conventional instructions + Enstilar© | No Intervention | Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Calcipotriene + Betamethasone Dipropionate | Drug | Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Adherent Participants | Rate of adherent patients, defined as dichotomized adherence rates obtained by number of days with applied medication with a selected cut-off of 80%, with adherence rates above 80% considered adherent | Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Dermatology Life Quality Index (DLQI) | Change from baseline to week 4 Description of Dermatology Life Quality Index (DLQI): A score from 0-30 [0, patients' quality of life not affected; 30, patients' quality of life severely affected by the skin disease]. The DLQI-scale is a summary of 10 questions on subscales, where patients' report how severely their quality of life has been affected for the last week (patient reported outcome measurements (PROM), each subscale have a score from 0 (not affected by skin disease) to 3 (severely affected by skin disease). The minimum score is 0 and the highest score is 30, a high score means worse outcome. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mathias Tiedemann Svendsen, MD, PhD | Department of Dermatology and Allergy Centre, Odense University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Dermatology and Allergy Centre | Odense C | 5000 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29415699 | Background | Svendsen MT, Andersen F, Andersen KH, Andersen KE. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial. BMC Dermatol. 2018 Feb 7;18(1):2. doi: 10.1186/s12895-018-0071-3. | |
| 29654699 | Result | Svendsen MT, Andersen F, Andersen KH, Pottegard A, Johannessen H, Moller S, August B, Feldman SR, Andersen KE. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol. 2018 Nov;179(5):1062-1071. doi: 10.1111/bjd.16667. Epub 2018 Jul 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | App as Intervention + Enstilar© | Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation. Enstilar 0.005%-0.064% Topical Foam |
| FG001 | Conventional Instructions + Enstilar© | Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM. Enstilar 0.005%-0.064% Topical Foam |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | App as Intervention + Enstilar© | Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation. Enstilar 0.005%-0.064% Topical Foam |
| BG001 | Conventional Instructions + Enstilar© |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Adherent Participants | Rate of adherent patients, defined as dichotomized adherence rates obtained by number of days with applied medication with a selected cut-off of 80%, with adherence rates above 80% considered adherent | Posted | Number | 95% Confidence Interval | percentage of participants | Week 4 |
|
Information on adverse events systematically reported at visits at baseline, week 4, 8 and 26 (6 months)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Conventional Instructions + App as Intervention + Enstilar© | Information obtained baseline, week 4, 8 and 26. Participants were treated with Enstilar© once daily when needed for 6 months |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Infection in knee prosthesis | Musculoskeletal and connective tissue disorders | Systematic Assessment | Infection in knee prosthesis. Not Associated with the use of Cal/BD foam. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| relapse of carcinoma in situ of the glottis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment | Not related to use of Cal/BD foam |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| M.D. Mathias Tiedemann Svendsen | Department of Dermatology, Odense University Hospital | +45 61265827 | m_tiedemann@hotmail.dk |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 3, 2016 | Feb 16, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C517164 | betamethasone dipropionate, calcipotriol drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| App | Device | App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm. |
|
|
| Baseline, week 4, 8 and 26 |
| Lattice-System Physician's Global Assessment (LS-PGA) | Change from baseline to week 4, 8 and 26 Lattice System Physican's Gloabal Assessment (LS-PGA) is a measure from 0-8 (0, patients skin clear; 8, patients' skin severely affected by psoriasis). The scale is a summary of three subscales: 1). thickness of psoriasis, 2). extent of scaling and 3). body surface ares (BSA) affected. The minimum score is 0 and the maximum score is 8, a high score represents a worse outcome. | Week 4, 8 and 26 |
Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM. Enstilar 0.005%-0.064% Topical Foam |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
|
|
|
| Secondary | Dermatology Life Quality Index (DLQI) | Change from baseline to week 4 Description of Dermatology Life Quality Index (DLQI): A score from 0-30 [0, patients' quality of life not affected; 30, patients' quality of life severely affected by the skin disease]. The DLQI-scale is a summary of 10 questions on subscales, where patients' report how severely their quality of life has been affected for the last week (patient reported outcome measurements (PROM), each subscale have a score from 0 (not affected by skin disease) to 3 (severely affected by skin disease). The minimum score is 0 and the highest score is 30, a high score means worse outcome. | Patients lost to follow-up | Posted | Mean | 95% Confidence Interval | units on a scale | Baseline, week 4, 8 and 26 |
|
|
|
|
| Secondary | Lattice-System Physician's Global Assessment (LS-PGA) | Change from baseline to week 4, 8 and 26 Lattice System Physican's Gloabal Assessment (LS-PGA) is a measure from 0-8 (0, patients skin clear; 8, patients' skin severely affected by psoriasis). The scale is a summary of three subscales: 1). thickness of psoriasis, 2). extent of scaling and 3). body surface ares (BSA) affected. The minimum score is 0 and the maximum score is 8, a high score represents a worse outcome. | Lost to follow-up | Posted | Mean | 95% Confidence Interval | units on a scale | Week 4, 8 and 26 |
|
|
|
|
| 0 |
| 66 |
| 0 |
| 66 |
| 22 |
| 66 |
| EG001 | App as Intervention + Enstilar© | Information obtained baseline, week 4, 8 and 26. Participants were treated with Enstilar© once daily when needed for 6 months | 0 | 68 | 1 | 68 | 20 | 68 |
|
|
| Worsening of chronic obstructive pumonary disease (COPD) | Respiratory, thoracic and mediastinal disorders | Systematic Assessment | Associated to accidentally inhaling gas from canister containing Cal/BD foam |
|
| Nausea | Ear and labyrinth disorders | Systematic Assessment |
|
| Elevated liver enzymes | Hepatobiliary disorders | Systematic Assessment | Elevated liver enzymes after treatment with methotrexate. Not related to use of Cal/BD foam |
|
| Elevated creatinin levels | Renal and urinary disorders | Systematic Assessment |
|
| Skin manifestations | Skin and subcutaneous tissue disorders | Systematic Assessment | 11 different skin manifestations not directly related to use of Enstilar |
|
| various musculoskelatal disorders | Musculoskeletal and connective tissue disorders | Systematic Assessment | Not related to the use of Cal/BD foam |
|
| Fainting | Vascular disorders | Systematic Assessment | Fainting not related to use of Cal/BD foam |
|
| Lung and skin infections | Infections and infestations | Systematic Assessment | Not related to the use of Cal/BD foam |
|
Not provided
Not provided
Not provided
| Change from baseline to week 8 |
|
|
| Change from baseline to week 26 |
|
|
| 0.545 |
| Coefficient |
| -0.415 |
| 2-Sided |
| 95 |
| -1.770 |
| 0.939 |
| Superiority |
| DLQI: Change from baseline to week 8 | Regression, Linear | 0.450 | Coefficient | -0.581 | 2-Sided | 95 | -2.099 | 0.938 | Superiority |
| DLQI: Change from baseline to week 26 | Regression, Linear | 0.348 | Coefficient | -0.770 | 2-Sided | 95 | -2.389 | 0.848 | Superiority |
| Change from baseline to week 8 |
|
|
| Change from baseline to week 26 |
|
|
| 0.662 |
| Coefficient |
| 0.091 |
| 2-Sided |
| 95 |
| -0.321 |
| 0.504 |
| Superiority |
| LS-PGA: Change from baseline to week 26 | Regression, Linear | 0.424 | Coefficient | 0.180 | 2-Sided | 95 | -0.264 | 0.625 | Superiority |